Krystal Biotech (Krystal Biotech) EPS (Diluted) : $0.09 (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech EPS (Diluted)?

Krystal Biotech's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.09.

Krystal Biotech's EPS (Basic) for the three months ended in Dec. 2023 was $0.32. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.19.

Krystal Biotech's EPS without NRI for the three months ended in Dec. 2023 was $0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.16.

During the past 3 years, the average EPS without NRIGrowth Rate was -10.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -28.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Krystal Biotech's highest 3-Year average EPS without NRI Growth Rate was -4.90% per year. The lowest was -64.60% per year. And the median was -47.80% per year.

Krystal Biotech EPS (Diluted) Historical Data

The historical data trend for Krystal Biotech's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech EPS (Diluted) Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.20

-1.71

-3.13

-5.49

0.39

Krystal Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-1.25	-1.76	-1.25	2.79	0.31

Competitive Comparison of Krystal Biotech's EPS (Diluted)

For the Biotechnology subindustry, Krystal Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krystal Biotech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's PE Ratio falls into.

Krystal Biotech EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Krystal Biotech's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(10.932	-	0)	/	27.752
	=	0.39

Krystal Biotech's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(8.692	-	0)	/	28.854
	=	0.30

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09

Krystal Biotech (NAS:KRYS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Krystal Biotech EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech (Krystal Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.

Executives

Krish S Krishnan	director, 10 percent owner, officer: President and CEO	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan	director, 10 percent owner, officer: Chief Operating Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Andrew C. Orth	officer: Chief Commercial Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano	officer: Chief Accounting Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi	director	61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Jennifer Chien	officer: Chief Commercial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby	director	C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v.	10 percent owner	POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000